𝗪𝗛𝗢 𝗹𝗮𝘂𝗻𝗰𝗵𝗲𝘀 𝗳𝗶𝗿𝘀𝘁 𝗴𝗹𝗼𝗯𝗮𝗹 𝗚𝗟𝗣-𝟭 𝗴𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲 𝗳𝗼𝗿 𝗼𝗯𝗲𝘀𝗶𝘁𝘆 𝗰𝗮𝗿𝗲
𝗪𝗛𝗢 𝗹𝗮𝘂𝗻𝗰𝗵𝗲𝘀 𝗳𝗶𝗿𝘀𝘁 𝗴𝗹𝗼𝗯𝗮𝗹 𝗚𝗟𝗣-𝟭 𝗴𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲 𝗳𝗼𝗿 𝗼𝗯𝗲𝘀𝗶𝘁𝘆 𝗰𝗮𝗿𝗲
The WHO released its first global guideline for GLP-1 obesity treatment, recognizing obesity as a chronic disease. Long-term care combined with therapy is key.
𝗪𝗛𝗢 𝗹𝗮𝘂𝗻𝗰𝗵𝗲𝘀 𝗳𝗶𝗿𝘀𝘁 𝗴𝗹𝗼𝗯𝗮𝗹 𝗚𝗟𝗣-𝟭 𝗴𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲 𝗳𝗼𝗿 𝗼𝗯𝗲𝘀𝗶𝘁𝘆 𝗰𝗮𝗿𝗲
This week, the World Health Organization released its first global guideline on the use of GLP-1 therapies for the treatment of obesity in adults. Obesity is now clearly defined as a 𝗰𝗵𝗿𝗼𝗻𝗶𝗰, 𝗿𝗲𝗹𝗮𝗽𝘀𝗶𝗻𝗴 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝗿𝗲𝗾𝘂𝗶𝗿𝗶𝗻𝗴 𝗹𝗶𝗳𝗲𝗹𝗼𝗻𝗴 𝗰𝗮𝗿𝗲, not temporary solutions.
𝗪𝗵𝗮𝘁 𝘁𝗵𝗲 𝗴𝘂𝗶𝗱𝗲𝗹𝗶𝗻𝗲 𝘀𝗮𝘆𝘀:
🔸 WHO recommends 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝗚𝗟𝗣-𝟭 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗳𝗼𝗿 𝗮𝗱𝘂𝗹𝘁𝘀 𝘄𝗶𝘁𝗵 𝗼𝗯𝗲𝘀𝗶𝘁𝘆
🔸 𝗕𝗲𝘀𝘁 𝗼𝘂𝘁𝗰𝗼𝗺𝗲𝘀 𝗮𝗿𝗲 𝗮𝗰𝗵𝗶𝗲𝘃𝗲𝗱 𝘄𝗵𝗲𝗻 𝗺𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗶𝘀 𝗰𝗼𝗺𝗯𝗶𝗻𝗲𝗱 𝘄𝗶𝘁𝗵 𝗶𝗻𝘁𝗲𝗻𝘀𝗶𝘃𝗲 𝗯𝗲𝗵𝗮𝘃𝗶𝗼𝘂𝗿𝗮𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 including diet, physical activity and structured support
🔸 𝗠𝗲𝗱𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗮𝗹𝗼𝗻𝗲 𝘄𝗶𝗹𝗹 𝗻𝗼𝘁 𝘀𝗼𝗹𝘃𝗲 𝘁𝗵𝗲 𝗼𝗯𝗲𝘀𝗶𝘁𝘆 𝗰𝗿𝗶𝘀𝗶𝘀
🔸 𝗖𝗼𝘂𝗻𝘁𝗿𝗶𝗲𝘀 𝗮𝗿𝗲 𝘂𝗿𝗴𝗲𝗱 𝘁𝗼 𝗯𝘂𝗶𝗹𝗱 𝗮 𝗳𝗮𝗶𝗿, 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗲𝗱 𝗮𝗻𝗱 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗹𝗲 𝗼𝗯𝗲𝘀𝗶𝘁𝘆 𝗲𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺, with prevention, early diagnosis, multimodal treatment and long-term follow-up at its core.
WHO further highlights that 𝗶𝗺𝗽𝗹𝗲𝗺𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗱𝗲𝗽𝗲𝗻𝗱𝘀 𝗼𝗻 𝗮𝗰𝗰𝗲𝘀𝘀, 𝗽𝗿𝗲𝗽𝗮𝗿𝗲𝗱 𝗵𝗲𝗮𝗹𝘁𝗵 𝘀𝘆𝘀𝘁𝗲𝗺𝘀 𝗮𝗻𝗱 𝗽𝗲𝗿𝘀𝗼𝗻-𝗰𝗲𝗻𝘁𝗿𝗲𝗱 𝗰𝗮𝗿𝗲, and explicitly points to 𝗱𝗶𝗴𝗶𝘁𝗮𝗹 𝘁𝗼𝗼𝗹𝘀 𝗮𝗻𝗱 𝘁𝗲𝗹𝗲𝗵𝗲𝗮𝗹𝘁𝗵 𝗮𝘀 𝗲𝗻𝗮𝗯𝗹𝗲𝗿𝘀 of adherence, follow-up and patient empowerment.
𝗪𝗵𝗮𝘁 𝘁𝗵𝗶𝘀 𝗺𝗲𝗮𝗻𝘀 𝗳𝗼𝗿 𝗬𝗮𝘇𝗲𝗻This is exactly how we work. At Yazen Health, we combine modern obesity medications with dietitians, psychologists and long-term digital follow-up. Sustainable results come from treating obesity as the chronic disease it is
🧡🔗 Celletti et al. 2025. WHO Guideline on GLP-1 Therapies for Obesity. JAMA (based on WHO guideline): https://lnkd.in/dNEXk5Yy🔗 WHO full guideline: https://lnkd.in/dN2rZhJj
